Bosulif's Primary Indication and Patent Coverage
Bosulif (bosutinib) is approved by the FDA for chronic myeloid leukemia (CML), specifically chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) CML in adults resistant or intolerant to prior therapy, and newly diagnosed chronic phase Ph+ CML.[1] Patent protections center on this oncology area, with DrugPatentWatch listing over 20 U.S. patents tied to bosutinib, many expiring between 2026 and 2034, covering the compound, formulations, and methods of use in CML treatment.[2]
Strongest Patent Protections by Therapeutic Area
Pfizer holds the strongest protections in chronic myeloid leukemia (CML), where bosutinib's kinase inhibitor mechanism targets BCR-ABL mutations. Key patents include:
- US 7,342,013 (expires 2026) for the bosutinib compound itself, broadly protecting its use in Ph+ leukemias.[2]
- US 8,461,167 and US 9,090,558 (expire 2029-2030) for specific CML treatment methods, including resistant cases.[2]
These create a dense "patent thicket" blocking generics until at least 2029, with pediatric exclusivity extending some to 2030.[2][3]
No significant patents extend to other therapeutic areas like solid tumors or non-CML leukemias; protections are narrowest outside CML, with method-of-use claims rarely litigated elsewhere.[2]
When Do Key Patents Expire?
| Patent | Focus | Expiration |
|--------|--------|------------|
| US 7,342,013 | Bosutinib compound (CML use) | Jan 2026 |
| US 8,461,167 | CML treatment methods | Sep 2029 |
| US 10,093,665 | Formulations for CML | May 2034[2] |
Orange Book listings confirm 17 patents for CML indications, with challenges from generics (e.g., Teva) ongoing in Paragraph IV litigation, likely delaying entry until 2030.[2][4]
Biosimilar and Generic Threats to CML Protections
Generic bosutinib faces hurdles until 2029 due to method-of-use patents, but compound patent expiry in 2026 opens formulation challenges. No biosimilars approved yet; EU patent (EP 1316550) expires 2025, potentially earlier entry in Europe.[2][5] Patients report access issues post-patent cliffs in similar TKIs like imatinib.
How Bosulif Patents Compare to Other TKIs
Bosulif's CML protections outlast Glivec (imatinib, generics since 2016) but trail Sprycel (dasatinib, key patents to 2027). Litigation has upheld Pfizer's claims against Mylan and Apotex, strengthening CML exclusivity versus competitors.[2][6]
Sources
[1]: FDA Label for Bosulif
[2]: DrugPatentWatch: Bosutinib Patents
[3]: FDA Orange Book
[4]: USPTO Litigation Dockets
[5]: EMA Bosutinib Info
[6]: CourtListener: Pfizer v. Teva